伴侣动物耳部感染治疗市场 - 按药物类型、动物类型、药物类型、给药方式、疾病类型、配销通路- 全球预测 2024 - 2032

由于狗和猫等伴侣动物耳部感染盛行率不断上升，2024年至2032年间伴侣动物耳部感染治疗市场规模的复合年增长率可能为6.8%。根据美国养犬俱乐部的数据，大约 20% 的狗患有某种形式的耳部疾病，可能会影响一隻或两隻耳朵。环境过敏原、耳螨、细菌或酵母菌过度生长以及解剖学倾向等耳部感染数量的增加将随后推动市场成长。

此外，兽医技术的进步促进了伴侣动物耳部感染创新治疗方案的发展。这些进步包括引入新型药物传输系统，例如长效滴耳剂和局部製剂，可提高治疗效果和患者依从性。宠物医疗保健产业的扩张，加上伴侣动物的日益普及，特别是在城市地区，将进一步促进该产业的扩张。

伴侣动物耳部感染治疗产业根据药物类型、动物类型、药物类型、给药方式、疾病类型、配销通路和地区进行细分。

从给药方式来看，由于口服药物的便利性和有效性，预计到 2032 年，口服药物的市场规模复合年增长率将达到 6.8%。口服抗生素和抗真菌药物提供了一种对抗感染的系统方法，可到达仅透过局部治疗难以到达的耳道区域。此外，兽药的进步促进了口服药物的开发，其安全性和适口性得到改善，从而提高了患者的依从性和治疗成功率。

伴侣动物耳部感染治疗产业的药局配销通路部分预计在 2024 年至 2032 年期间复合年增长率为 6.9%。宠物拥有率的提高和对宠物医疗保健的认识的提高将推动对耳部感染等常见疾病的便捷且可及的治疗方案的需求。在药局购买耳部感染治疗药物和其他宠物护理产品的便利性进一步吸引了寻求快速且经济高效的解决方案来管理宠物健康的宠物主人。

由于严格的宠物医疗保健标准法规以及对预防性兽医护理的日益重视，欧洲伴侣动物耳部感染治疗行业规模在 2024 年至 2032 年间将实现 6.8% 的复合年增长率。德国、法国和英国等国家的宠物拥有率较高，加上宠物主人可支配收入的不断增长，将创造有利的市场环境。此外，兽医学的进步，包括提供专门的耳部感染治疗产品和提高治疗效果的诊断工具，将推动区域市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 全球宠物拥有率不断上升
    • 兽医医学不断进步
    • 宠物耳部感染盛行率上升
  • 产业陷阱与挑战
    • 缺乏合规性
    • 药物的副作用
• 成长潜力分析
• 管道评估
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类型，2018 - 2032

• 主要趋势
• 抗生素
  • 头孢菌素类
  • 青霉素类
  • 氟喹诺酮类药物
  • 咪唑
  • 其他抗生素
• 抗霉菌药
• 皮质类固醇
• 清洁剂
• 其他药物种类

第 6 章：市场估计与预测：按动物类型，2018 - 2032

• 主要趋势
• 小狗
• 猫
• 马匹
• 其他动物类型

第 7 章：市场估计与预测：按药物类型，2018 年 - 2032 年

• 主要趋势
• 场外交易
• 处方

第 8 章：市场估计与预测：按管理模式划分，2018 年 - 2032 年

• 主要趋势
• 奥迪克
• 口服
• 注射用
• 专题

第 9 章：市场估计与预测：按疾病类型，2018 年 - 2032 年

• 主要趋势
• 外耳道炎
• 中耳炎
• 内耳炎

第 10 章：市场估计与预测：按配销通路划分，2018 年 - 2032 年

• 主要趋势
• 兽医院药房
• 药局
• 宠物专卖店
• 电子商务

第 11 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要动向：按地区
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 12 章：公司简介

• Bayer AG
• Ceva Sante Animale
• Dechra Pharmaceuticals PLC
• Elanco Animal Health Incorporated
• Entod International
• Merck & Co., Inc.
• Nextmune
• Penn Veterinary Supply, Inc.
• Piedmont Animal Health, Inc.
• Vedco, Inc.
• Vetnique Labs
• Vetoquinol S.A.
• Virbac S.A.
• Wedgewood Village Pharmacy, LLC
• Zoetis Inc.

Companion animal ear infection treatment market size is likely to register 6.8% CAGR between 2024 to 2032, driven by the increasing prevalence of ear infections among companion animals, such as dogs and cats. As per American Kennel Club, around 20% dogs have some form of ear disease, which could affect one or both ears. The rising count of ear infections including environmental allergens, ear mites, bacterial or yeast overgrowth, and anatomical predispositions will subsequently boost the market growth.

Moreover, technological advancements in veterinary medicine have led to the development of innovative treatment options for companion animal ear infections. These advancements include the introduction of novel drug delivery systems, such as long-acting ear drops and topical formulations, which enhance treatment efficacy and patient compliance. The expansion of the pet healthcare sector, coupled with the increasing adoption of companion animals, particularly in urban areas, will further contribute to the industry expansion.

The companion animal ear infection treatment industry is segmented based on drug type, animal type, medication type, mode of administration, disease type, distribution channel and region.

By mode of administration, the market size from the oral segment is anticipated to witness 6.8% CAGR through 2032, attributed to the convenience and efficacy of oral medications. Oral antibiotics and antifungal medications offer a systemic approach to combating infections, reaching areas of the ear canal that may be difficult to access with topical treatments alone. Additionally, advancements in veterinary pharmaceuticals have led to the development of oral medications with improved safety profiles and palatability for increasing patient compliance and treatment success rates.

The drug store distribution channel segment in the companion animal ear infection treatment industry is estimated to strike 6.9% CAGR during 2024-2032. Increasing pet ownership rates and awareness about pet healthcare will drive the demand for convenient and accessible treatment options for common ailments like ear infections. The convenience of purchasing ear infection treatments alongside other pet care products at drug stores is further appealing to pet owners seeking quick and cost-effective solutions to manage the health of their pets.

Europe companion animal ear infection treatment industry size will record 6.8% CAGR between 2024-2032, attributed to stringent regulations governing pet healthcare standards and the increasing emphasis on preventive veterinary care. The high pet ownership rates in countries like Germany, France, and the U.K., coupled with the growing disposable income of pet owners will foster a conducive market environment. Furthermore, advancements in veterinary medicine, including the availability of specialized ear infection treatment products and diagnostic tools to enhance the efficacy of treatment will drive regional the market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing rate of pet ownership globally
    • 3.2.1.2 Growing advancements in veterinary medicine
    • 3.2.1.3 Rising prevalence of ear infections among pets
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of compliance
    • 3.2.2.2 Side effects of medications
• 3.3 Growth potential analysis
• 3.4 Pipeline assessment
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Antibiotics
  • 5.2.1 Cephalosporins
  • 5.2.2 Penicillins
  • 5.2.3 Fluoroquinolones
  • 5.2.4 Imidazole
  • 5.2.5 Other antibiotics
• 5.3 Antifungals
• 5.4 Corticosteroids
• 5.5 Cleaning agents
• 5.6 Other drug types

Chapter 6 Market Estimates and Forecast, By Animal Type, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Dogs
• 6.3 Cats
• 6.4 Horses
• 6.5 Other animal types

Chapter 7 Market Estimates and Forecast, By Medication Type, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 OTC
• 7.3 Prescription

Chapter 8 Market Estimates and Forecast, By Mode of Administration, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Otic
• 8.3 Oral
• 8.4 Parenteral
• 8.5 Topical

Chapter 9 Market Estimates and Forecast, By Disease Type, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Otitis externa
• 9.3 Otitis media
• 9.4 Otitis interna

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Veterinary hospital pharmacies
• 10.3 Drug stores
• 10.4 Pet specialty stores
• 10.5 E-commerce

Chapter 11 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 11.1 Key trends, by region
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 Rest of Asia Pacific
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Rest of Latin America
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 Rest of Middle East and Africa

Chapter 12 Company Profiles

• 12.1 Bayer AG
• 12.2 Ceva Sante Animale
• 12.3 Dechra Pharmaceuticals PLC
• 12.4 Elanco Animal Health Incorporated
• 12.5 Entod International
• 12.6 Merck & Co., Inc.
• 12.7 Nextmune
• 12.8 Penn Veterinary Supply, Inc.
• 12.9 Piedmont Animal Health, Inc.
• 12.10 Vedco, Inc.
• 12.11 Vetnique Labs
• 12.12 Vetoquinol S.A.
• 12.13 Virbac S.A.
• 12.14 Wedgewood Village Pharmacy, LLC
• 12.15 Zoetis Inc.